Opendata, web and dolomites

CAtALySt SIGNED

NeurescueTM: Computer- controlled aortic occlusion device for the treatment of cardiac arrest

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CAtALySt project word cloud

Explore the words cloud of the CAtALySt project. It provides you a very rough idea of what is the project "CAtALySt" about.

aorta    competitive    patients    generation    position    algorithm    unrivalled    proposition    validation    business    portable    predicted    neurescuetm    function    price    united    barriers    market    catalyst    outside    blood    building    rate    damage    safe    adoption    sca    preservation    revenue    proposes    profitable    back    paris    run    samu    perfusion    medical    million    heart    tissue    10    clinical    marking    with    standard    normal    company    total    hospital    pressure    premises    computer    holding    accuracy    rates    234m    solution    40    university    23    aortic    assistance    health    demonstration    changing    ce    vital    critical    brain    2020    portability    broad    public    survival    worldwide    window    sudden    accurate    emergency    cardiac    light    neurescue    89    denmark    synergy    device    occlusion    severe    sensor    combines    resuscitation    roject    projected    incidence    radically    organs    necker    france    game    gathering    below    2030    intervention    aps    introduction    patient    works    inside    data    commercial    arrests    de    post    chu    ready    episodes    burden    time    surpass    probability    roll    aggregated    neur    germany    odense   

Project "CAtALySt" data sheet

The following table provides information about the project.

Coordinator
NEURESCUE APS 

Organization address
address: NJALSGADE 76
city: KOBENHAVN
postcode: 2300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website https://www.neurescue.com/home-eu/
 Total cost 2˙331˙787 €
 EC max contribution 1˙632˙251 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2021-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEURESCUE APS DK (KOBENHAVN) coordinator 1˙632˙251.00

Map

 Project objective

With a worldwide incidence expected to increase from 9,23 million cases by 2020 to 10,89 million cases by 2030, Sudden Cardiac Arrests (SCA) episodes are today recognized as a public health problem leading to severe brain tissue damage with survival rates below 10%. Neurescue Aps (NEUR) proposes to address the SCA burden by bringing to light a game changing solution - NeurescueTM – capable of extending the critical time window necessary to bring a SCA patient back to normal heart function, and therefore holding the potential to radically improve the emergency assistance provided to SCA patients, allowing for 20- 40% of increase in the survival rate of SCA patients. Due to an algorithm-run sensor technology which enables a safe and accurate computer-controlled aortic occlusion, NeurescueTM is a portable medical device that, not only increases the blood perfusion pressure necessary for vital organs preservation (i.e. brain and heart), but also works in synergy with standard resuscitation procedures increasing their probability of success. NeurescueTM is the only device in the market that combines portability with the accuracy required for a safe medical intervention (i.e. aorta occlusion) to SCA patients both inside and outside the hospital premises. With a price-competitive technology and with an unrivalled value proposition, NEUR is in a strong position to build a profitable business. Building on the project activities, NeurescueTM the device is projected to be ready for commercial roll-out by 2020 with a predicted total aggregated revenue for the company of over €234M throughout the 5 years post- roject. CAtALySt project aims to surpass the main market barriers associated with the market introduction of NeurescueTM, namely gathering data for CE-marking and broad clinical demonstration for market awareness and to ensure end-user medical adoption. Clinical validation will be held at Odense University Hospital in Denmark, and further clinical evidence generation at Hospital SAMU de Paris CHU Necker in France, a leading university hospital in Germany, and a leading university hospital in the United States.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CATALYST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CATALYST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More